Abstract
A fair amount of data indicates that bradykinin and lysyl-bradykinin exert arterial, cardiac and renal effects which afford protection against organ damage in diseases, especially in the settings of ischemia or diabetes. The concept of kinins acting as therapeutic agents is supported by the wide use of angiotensin I-converting enzyme (ACE) inhibitors. These inhibitors indeed potentiate kinin action by inhibiting kinin degradation. Experimental evidence strongly suggests that the cardiac and renal effects of ACE inhibitors are due, at least in part, to kinins. Angiotensin AT1 receptor antagonists act also partly through kinins. This paper reviews available evidence supporting a role for kinins in the therapeutic effect of current drugs. It then discusses the opportunity to develop new drugs based on kinin action. Direct activation of the kinin B2 receptor by pharmacological agonists might provide higher therapeutic benefit than existing kinin- potentiating drugs. Possible occurrence of side effects is however a concern.
Keywords: Bradykinin, kinin receptors, angiotensin-converting enzyme inhibitors, angiotensin receptor antagonists, kinin receptor agonists, cardiovascular diseases, cardiac ischemia, diabetic nephropathy, vascular endothelial cells, kallikrein-kinin systems
Current Pharmaceutical Design
Title: Kinins as Therapeutic Agents in Cardiovascular and Renal Diseases
Volume: 17 Issue: 25
Author(s): Francois Alhenc-Gelas, Nadine Bouby, Christine Richer, Louis Potier, Ronan Roussel and Michel Marre
Affiliation:
Keywords: Bradykinin, kinin receptors, angiotensin-converting enzyme inhibitors, angiotensin receptor antagonists, kinin receptor agonists, cardiovascular diseases, cardiac ischemia, diabetic nephropathy, vascular endothelial cells, kallikrein-kinin systems
Abstract: A fair amount of data indicates that bradykinin and lysyl-bradykinin exert arterial, cardiac and renal effects which afford protection against organ damage in diseases, especially in the settings of ischemia or diabetes. The concept of kinins acting as therapeutic agents is supported by the wide use of angiotensin I-converting enzyme (ACE) inhibitors. These inhibitors indeed potentiate kinin action by inhibiting kinin degradation. Experimental evidence strongly suggests that the cardiac and renal effects of ACE inhibitors are due, at least in part, to kinins. Angiotensin AT1 receptor antagonists act also partly through kinins. This paper reviews available evidence supporting a role for kinins in the therapeutic effect of current drugs. It then discusses the opportunity to develop new drugs based on kinin action. Direct activation of the kinin B2 receptor by pharmacological agonists might provide higher therapeutic benefit than existing kinin- potentiating drugs. Possible occurrence of side effects is however a concern.
Export Options
About this article
Cite this article as:
Alhenc-Gelas Francois, Bouby Nadine, Richer Christine, Potier Louis, Roussel Ronan and Marre Michel, Kinins as Therapeutic Agents in Cardiovascular and Renal Diseases, Current Pharmaceutical Design 2011; 17 (25) . https://dx.doi.org/10.2174/138161211797416002
DOI https://dx.doi.org/10.2174/138161211797416002 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Hutchinson-Gilford Progeria Syndrome: An Overview of the Molecular Mechanism, Pathophysiology and Therapeutic Approach
Current Gene Therapy Withdrawal Notice: Therapeutic Options for Treatment of COVID-19: A Review from Repurposed Drugs to New Drug Targets
Current Drug Targets Prevention of Sudden Cardiac Death in Hemodialysis Patients
Cardiovascular & Hematological Disorders-Drug Targets How to Recognize Epicardial Origin of Ventricular Tachycardias?
Current Cardiology Reviews Inhibitory Effect of Fruit Juices on the Doxorubicin Metabolizing Activity of Carbonyl Reductase 1
Drug Metabolism Letters Antiapoptotic Effect of Novel Compound from Herba leonuri-Leonurine (SCM-198): A Mechanism Through Inhibition of Mitochondria Dysfunction in H9c2 Cells
Current Pharmaceutical Biotechnology Editorial: Cocaine and Cerebral Small Vessel: Is it a Negative Factor for Intravenous Thrombolysis?
Current Vascular Pharmacology Cardiac Dysfunction in Rats with Dietary-Induced Insulin Resistance Associated with Pharmacologically-induced Dyslipidemia
Current Pharmaceutical Design MicroRNAs: A Critical Regulator and a Promising Therapeutic and Diagnostic Molecule for Diabetic Cardiomyopathy
Current Gene Therapy Animal Models of Diabetes Mellitus: Relevance to Vascular Complications
Current Pharmaceutical Design Heart Failure in Diabetes Mellitus: An Updated Review
Current Pharmaceutical Design MicroRNA-34a Promotes Cardiomyocyte Apoptosis Post Myocardial Infarction Through Down-regulating Aldehyde Dehydrogenase 2
Current Pharmaceutical Design Molecular Mechanisms of Inherited Arrhythmias
Current Genomics The Complex Biology of FOXO
Current Drug Targets Understanding and Avoiding Antiretroviral Adverse Events
Current Pharmaceutical Design PDE5 Inhibitor Treatment Options for Urologic and Non-Urologic Indications: 2012 Update
Current Pharmaceutical Design Combating Obesity by Targeting Nuclear Receptors
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Autoimmunity and Celiac Disease
Mini-Reviews in Medicinal Chemistry Cardiovascular Disease in Patients with Diabetic Nephropathy
Current Molecular Medicine Apoptosis in Anthracycline Cardiomyopathy
Current Pediatric Reviews